Early Prostate Cancer Detected in Molecular-Based Urine Test
PHILADELPHIA (April 2, 2000) -- Researchers at Fox Chase Cancer Center in Philadelphia, Pa. say prostate cancer can be detected in urine. The findings of a new study were presented today at the American Association for Cancer Research in San Francisco.
"Prostate cancer is curable if detected early and it is likely that there are cancer cells in body fluids years before cancer is clinically detectable. If we can find those cells, we can cure more prostate cancers," explained Paul Cairns, Ph.D. of Fox Chase Cancer Center.
Cairns and his colleagues at Johns Hopkins University (JHU), chose to screen urine DNA for a common, early genetic change unique to cancer cells called hypermethylation at the glutathione-S-transferase (GSTP1) gene using a sensitive PCR (polymerase chain reaction) test. GSTP1 hypermethylation is found in more than 90% of prostate cancers but not in normal tissues or in BPH, making it a very specific marker for the disease.
Investigators collected tumor samples and urine specimens from 28 men known to have surgically curable prostate cancers. Specimens were coded to prevent investigator bias. Of the 28 tumor DNAs, 22 showed GSTP1 methylation and could be compared with urine samples. For 6 of these 22 tumors, the corresponding urine DNA was also positive for GSTP1 methylation, confirming the potential of this test to detect curable prostate cancers. There were no false-positive results.
"We are optimistic that future research and continuing improvements in molecular technology will increase the detection rate. Screening tests should be reliable, inexpensive, and noninvasive. Urine tests meet these standards," said Dr. Cairns. "Furthermore, we already know from Dr. Sidransky's (JHU) work that a urine test can detect almost all bladder cancers and many kidney cancers. In the future, it's quite possible that the same urine specimen could be used to test for prostate, bladder and kidney cancer."
Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the center's web site at: www.fccc.edu.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy6 Moore at 215-728-2700.